Mustang Bio Inc.
Division of Fortress Biotech Inc.
Latest From Mustang Bio Inc.
Gene therapy and lambda interferon products are highlighted in the new Review Pathways section of the US FDA Performance Tracker, which keeps track of breakthrough therapy (BTD), regenerative medicine advanced therapy (RMAT), qualified infectious disease product (QIDP) designations and biosimilar submissions.
Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.
Tech Transfer Roundup: Mustang, Nationwide Children’s Hospital Collaborate In Pediatric Glioblastoma
Partnership will test Mustang’s MB-101 with a second-generation oncolytic HSV-1 virus for potential in treating brain cancer. Canadian biotech launched by CCAB to fight the same cancer.
Fortress Biotech’s subsidiary will add the lentiviral gene therapy now in pair of Phase I/II trials to its pipeline. RXi partners with Karolinska to advance its self-delivering RNAi technology, while Avalon enlists Weill Cornell to enhance its CAR-T capabilities.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Mustang Therapeutics Inc.
- North America
- Company Type
- Parent & Subsidiaries
- Fortress Biotech Inc.
- Senior Management
Manuel Litchman, MD, Pres. & CEO
Brian Achenbach, VP, Finance & Corp. Controller
Sadik Kassim, PhD, CSO
Knut Niss, PhD, CTO
Martina A Sersch, MD, PhD, CMO
- Contact Info
Mustang Bio Inc.
Phone: (781) 652-4500
2 Gansevoort St.
New York, NY 10014
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.